State Board of Administration of Florida Retirement System Sells 26,060 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

State Board of Administration of Florida Retirement System reduced its holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) by 49.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 27,015 shares of the company’s stock after selling 26,060 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Karyopharm Therapeutics were worth $92,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the business. Fox Run Management L.L.C. acquired a new position in Karyopharm Therapeutics in the fourth quarter valued at approximately $98,000. Los Angeles Capital Management LLC raised its holdings in Karyopharm Therapeutics by 29.6% in the fourth quarter. Los Angeles Capital Management LLC now owns 101,917 shares of the company’s stock worth $347,000 after purchasing an additional 23,260 shares during the period. Birchview Capital LP raised its holdings in Karyopharm Therapeutics by 8.2% in the fourth quarter. Birchview Capital LP now owns 291,332 shares of the company’s stock worth $991,000 after purchasing an additional 22,000 shares during the period. Redwood Wealth Management Group LLC acquired a new stake in Karyopharm Therapeutics in the fourth quarter worth $113,000. Finally, Janney Montgomery Scott LLC acquired a new stake in Karyopharm Therapeutics in the fourth quarter worth $34,000. 96.13% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Karyopharm Therapeutics

In other news, EVP Reshma Rangwala sold 6,770 shares of the firm’s stock in a transaction dated Thursday, April 20th. The shares were sold at an average price of $4.05, for a total transaction of $27,418.50. Following the completion of the sale, the executive vice president now owns 158,230 shares in the company, valued at approximately $640,831.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Karyopharm Therapeutics news, EVP Sohanya Roshan Cheng sold 11,239 shares of Karyopharm Therapeutics stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $3.03, for a total value of $34,054.17. Following the completion of the sale, the executive vice president now owns 210,687 shares in the company, valued at approximately $638,381.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Reshma Rangwala sold 6,770 shares of Karyopharm Therapeutics stock in a transaction dated Thursday, April 20th. The stock was sold at an average price of $4.05, for a total transaction of $27,418.50. Following the completion of the sale, the executive vice president now owns 158,230 shares of the company’s stock, valued at approximately $640,831.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 79,412 shares of company stock worth $252,484. 3.32% of the stock is owned by insiders.

Karyopharm Therapeutics Stock Performance

NASDAQ KPTI opened at $2.59 on Wednesday. The firm has a 50-day moving average of $3.44 and a 200-day moving average of $3.62. The stock has a market cap of $295.29 million, a PE ratio of -1.44 and a beta of 0.07. Karyopharm Therapeutics Inc. has a 52-week low of $2.28 and a 52-week high of $6.84.

Analyst Upgrades and Downgrades

KPTI has been the topic of a number of research analyst reports. Morgan Stanley dropped their price objective on shares of Karyopharm Therapeutics from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Friday, January 27th. Robert W. Baird dropped their price objective on shares of Karyopharm Therapeutics from $14.00 to $10.00 in a report on Friday, May 5th. HC Wainwright dropped their price objective on shares of Karyopharm Therapeutics from $16.00 to $10.00 in a report on Friday, May 5th. Finally, StockNews.com began coverage on shares of Karyopharm Therapeutics in a research report on Thursday, May 18th. They issued a “hold” rating for the company. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Karyopharm Therapeutics Profile

(Get Rating)

Karyopharm Therapeutics, Inc is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).